Compare GSK plc (GSK) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ON Holding AG — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while ON Holding AG trades at $35.05 (market cap $11.38B). The key difference: GSK plc is far larger — about 8.1× ON Holding AG's market cap, and GSK plc pays a 3.9% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ON Holding AG for 22 Days on average.
| GSK | ONON | |
|---|---|---|
Market Cap | $91.88B | $11.38B |
Volume | 7,730,529 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $50.63 |
52-Week Low | $43.24 | $26.76 |
Typical Hold Time | 93 Days | 22 Days |
Enterprise Value | $111.88B | $10.54B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
ONON stock trades at $35.09, up 5.63% with strong bullish momentum. The company demonstrates robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 versus $0.42 expected. Recent investor day announcements of a $1 billion buyback program and ambitious 2029 targets have fueled positive sentiment. Technical indicators show bullish moving averages but overbought RSI conditions.
Outlook remains positive with analyst consensus at $42.26 target (20% upside) and 74% buy ratings. Key opportunities include premium store expansion and new sports categories, while risks involve execution on growth targets and competitive pressures in athletic footwear. The stock's current valuation at 24x P/E reflects growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
